Burnet Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 4.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.01 Cr
as on 16-11-2024
- Company Age 42 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.75 Cr
as on 16-11-2024
- Revenue -8.48%
(FY 2023)
- Profit 69.60%
(FY 2023)
- Ebitda 13.23%
(FY 2023)
- Net Worth 38.94%
(FY 2023)
- Total Assets 10.45%
(FY 2023)
About Burnet Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 Cr and a paid-up capital of Rs 4.01 Cr.
The company currently has active open charges totaling ₹17.75 Cr.
Ram Tewari and Shiv Tewari serve as directors at the Company.
- CIN/LLPIN
U34232WB1982PTC035307
- Company No.
035307
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 1982
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Burnet Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Tewari  | Managing Director | 30-Sep-1982 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shiv Tewari | Director | 01-Jan-1983 | Current |
Financial Performance of Burnet Pharmaceuticals.
Burnet Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.48% decrease. The company also saw a substantial improvement in profitability, with a 69.6% increase in profit. The company's net worth Soared by an impressive increase of 38.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Burnet Pharmaceuticals?
In 2023, Burnet Pharmaceuticals had a public holding of 30.30%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jun 2024 | ₹5.76 Cr | Open |
Axis Bank Limited Creation Date: 28 Jul 2023 | ₹4.35 Cr | Open |
Axis Bank Limited Creation Date: 28 Dec 2021 | ₹3.00 M | Open |
How Many Employees Work at Burnet Pharmaceuticals?
Burnet Pharmaceuticals has a workforce of 131 employees as of Sep 16, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Burnet Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Burnet Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
